论文部分内容阅读
目的探讨瑞舒伐他汀钙片治疗老年人急性脑梗死的临床疗效。方法选取濮阳市人民医院神经内科2013年8月至2014年8月收治的急性脑梗死患者160例为研究对象,随机分为观察组和对照组。观察组80例,在常规治疗的基础上给予瑞舒伐他汀钙片和阿司匹林肠溶片治疗;对照组80例,在常规治疗的基础上给予阿司匹林肠溶片治疗,观察两组的临床疗效及治疗前后NHISS评分和ADL评分,评价临床疗效。结果疗程结束后,观察组总有效率为95.00%,显著高于对照组(77.50%),P<0.05;治疗前两组的神经功能缺损(NIHSS)评分和生活活动能力(ADL)评分比较差异未见统计学意义(P>0.05),治疗后观察组NHISS评分显著低于对照组(P<0.05),ADL评分显著高于对照组(P<0.05)。结论瑞伐他汀钙片治疗老年急性脑梗死能够显著降低患者的NHISS评分,提高ADL评分,临床疗效显著。
Objective To investigate the clinical efficacy of rosuvastatin calcium tablet in the treatment of acute cerebral infarction in the elderly. Methods 160 patients with acute cerebral infarction admitted to Department of Neurology, Puyang People’s Hospital from August 2013 to August 2014 were selected as study subjects and randomly divided into observation group and control group. 80 cases in the observation group were treated with rosuvastatin calcium tablets and aspirin enteric-coated tablets on the basis of routine treatment; 80 cases in the control group were given aspirin enteric-coated tablets on the basis of routine treatment, and the clinical efficacy and NHISS scores before and after treatment and ADL score, evaluation of clinical efficacy. Results After treatment, the total effective rate in observation group was 95.00%, which was significantly higher than that in control group (77.50%), P <0.05. There was significant difference between NIHSS score and ADL score There was no statistical significance (P> 0.05). After treatment, the NHISS score of the observation group was significantly lower than that of the control group (P <0.05), and the ADL score was significantly higher than that of the control group (P <0.05). Conclusion The treatment of revastatin calcium tablets in elderly patients with acute cerebral infarction can significantly reduce the patient’s NHISS score, improve ADL score, clinical efficacy significantly.